Psychedelic Research & Therapy Development (Dr. M. Scheidegger)

Our goal is to investigate the therapeutic potential of psychedelic compounds to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities. The suboptimal efficacy of currently available drugs in mental health care points towards an unmet clinical need to investigate novel approaches to combine pharmacotherapy and psychotherapy. Recently, psychedelics such as ketamine, psilocybin, ayahuasca and DMT were discovered to alleviate symptoms of depression, anxiety, and addictive behaviors in a rapid-acting manner. Based on the findings from our neuroscientific research, we are developing novel transformation-based therapies for the safe, rapid-acting and sustainable treatment of affective disorders.